AcelRx hammered (again) after FDA demands a new Zalviso study after all

John Carroll

When the FDA rejected 's drug/device for pain last summer, the biotech said no new trials were required–suggesting it could be back in front of regulators quickly–and investors cut the value of shares by more than 30%. This morning the biotech said a new is needed all, and investors responded by sending shares down by more than 40%.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS